The EMA’s COVID-19 task force has said “that there is currently insufficient evidence that inhaled corticosteroids are beneficial for people with COVID-19.” In addition, the task force said that “it could not exclude the possibility of harm from the use of inhaled corticosteroids in patients with COVID-19 who have normal levels of oxygen.”
Evidence cited by the task force includes disappointing results from a trial of Covis Pharma’s Alvesco ciclesonide MDI for the treatment of COVID-19 and an Oxford study of inhaled budesonide for the the treatment of COVID-19 that found some benefit.
The EMA noted that dexamethasone has been found to be useful in the treatment of COVID-19 but that “More evidence from clinical trials is necessary to establish the benefits of inhaled corticosteroids in people with COVID-19.”
Read the EMA announcement.
